ATIM-10. PHASE 2 TRIAL OF SL-701 A NOVEL IMMUNOTHERAPY COMPRISED OF SYNTHETIC SHORT PEPTIDES AGAINST GBM TARGETS IL-13Rα2 EphA2 AND SURVIVIN IN ADULTS WITH SECOND-LINE RECURRENT GBM

摘要

BACKGROUNDSL-701, a novel immunotherapy comprised of synthetic peptides elicits immune responses against overexpressed GBM targets: interleukin-13 receptor alpha-2 (IL-13Rα2), EphrinA2 (EphA2), and Survivin. Updated data reported from a multicenter, 2-stage Phase 2 clinical trial of SL-701 in HLA-A2+ adults with relapsed GBM.